Relafen 750, a novel compound of naproxen, offers a compelling example from a biochemical pharmacy perspective. Its process of action, mainly involving inhibition of cyclooxygenase enzymes and COX-1 and COX-2 – results to significant decrease in prostaglandin production. Considering our biochemical context, the drug's efficacy is directly related